ArticleJournal of cardiothoracic surgery2025
Evaluating the predictive value of the CALLY index for MACE events in STEMI patients: a comparative analysis across admission and discharge time points.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Albumin-Based Biomarkers and Adverse Outcomes in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Impact of a Prehospital Chest Pain Alert App-Mediated Prehospital-in-Hospital Coordination Model on Treatment Delays and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction: Protocol for a 4-Year Retrospective Real-World Cohort Study.JMIR research protocols · 2026Article
- Preoperative C-Reactive Protein-Albumin-Lymphocyte (CALLY) Score and the Risk of Acute Kidney Injury Following Cardiac Surgery: A Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Association of C-reactive protein-albumin-lymphocyte index and coronary artery calcification on major adverse cardiovascular events of dialysis patients with acute coronary syndrome.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSignificant mortality and morbidity are caused by ST-segment elevation myocardial infarction (STEMI), emphasising the necessity for reliable predictive instruments. The aim of this study is to assess the predictive value of the CALLY index at different points in time for the long-term prognosis of patients with STEMI who have undergone percutaneous coronary intervention (PCI).
methodsThis retrospective study included 421 patients diagnosed with STEMI. The C-reactive protein-albumin-lymphocyte(CALLY) Index was collected at admission, 12-48 h after PCI, and at discharge. Univariate and multivariate Cox proportional hazard models were employed to identify independent factors influencing the prognosis of STEMI. The receiver operating characteristic (ROC) curves were utilized to determine the optimal predictive value of the CALLY index. Additionally, Kaplan-Meier analysis was conducted to assess the relationship between the CALLY index and major adverse cardiovascular events (MACEs).
resultsThe primary outcome indicated that high levels of the CALLY index at 24 h post-PCI (threshold = 0.77) were significant independent prognostic factors for long-term MACEs among STEMI patients (hazard ratio,0.303; 95% confidence interval, 0.207-0.445; P < 0.001). Among the evaluated variables, the CALLY index at 24 h post-PCI exhibited the highest accuracy in predicting MACEs in STEMI patients during long-term follow-up (AUC: 0.712, P < 0.001). Furthermore, the CALLY index at 24 h post-PCI was significantly associated with no-reflow phenomenon (P = 0.006) and Gensini score (P < 0.001), demonstrating its relationship with coronary disease severity and reperfusion quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.